Defining the Target Volumes and Radiation Doses after Primary Systemic Therapy-Reference-Cited by-同舟云学术

Defining the Target Volumes and Radiation Doses after Primary Systemic Therapy

Published:2022 Issue: Volume: Page:333-340
ISSN:
Container-title:Breast Cancer Radiation Therapy
language:
Short-container-title:

Author:

Galper Shira L.,Jacobson Galia,Montero Angel

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-030-91170-6_43

Reference52 articles.

1. van der Hage JH, van de Velde CC, Mieog SJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;2:CD005002.

2. Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau J-F, Brezden-Masley C, Chia S, Dent S. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2016;2(6):751–60.

3. Li J, Chen S, Chen C, Di G, Liu G, Wu J, Shao Z. Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy. Oncotarget. 2017;8(11):18399.

4. Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):138–45.

5. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22(23):4691–9.